How Has the Opioid-Induced Constipation Treatment Market Evolved Historically and What is its Current Size?
The opioid-induced constipation treatment market has seen considerable growth due to a variety of factors.
• The opioid-induced constipation (OIC) treatment market has experienced robust growth. It will increase from $1.78 billion in 2024 to $1.9 billion in 2025, at a compound annual growth rate (CAGR) of 7.0%.
This growth is attributed to a growing elderly population, personalized treatments for OIC, availability of effective medications, rising opioid use, and increasing gastrointestinal disorders.
What Does Future Hold for The Opioid-Induced Constipation Treatment Market By 2029?
The opioid-induced constipation treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The opioid-induced constipation treatment market is projected to grow to $2.47 billion by 2029, with a CAGR of 6.7%.
This growth is attributed to faster drug approval processes, increased opioid analgesic use, higher R&D spending, and the development of biologic treatments. Trends include a focus on patient education, emerging targeted therapies, non-pharmacological treatments, biotechnological innovations, and increased investments in the field.
What Are The Primary Growth Drivers In The Opioid-Induced Constipation Treatment Market?
Growth in the opioid-induced constipation treatment market is being spurred on by the increasing use of opioids to manage both cancer and non-cancer related pain. Pain deriving from cancer and its associated treatments is the primary concern, but opioid use is also increasing to manage pain from non-cancer related conditions. The demand for efficient management of moderate to intense pain, taking into account factors such as pain intensity, duration, patient's response to other treatments, and the ultimate aim of improving life quality while minimizing addiction risk and side effects, is driving this trend. Opioid-induced constipation (OIC) treatment offers relief to patients dealing with pain from cancer and other conditions, from the constipation resulting from opioid use. This improves overall comfort levels, reinforces adherence to pain management plans, and enhances life quality without affecting pain relief efficacy. As an example, the Government of Canada reported in May 2021 that as many as 8.3 million Canadians could suffer from chronic pain by 2025, with that figure potentially reaching 9.0 million by 2030. Consequently, increased opioid use for pain relief in cancer and non-cancer patients is fueling the growth of the opioid-induced constipation treatment market.
What Is The Segmentation Of The Global Opioid-Induced Constipation Treatment Market?
The opioid-induced constipation treatment market covered in this report is segmented –
1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
4) By Prostaglandin: Lubiprostone
Pre-Book The Opioid-Induced Constipation Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Opioid-Induced Constipation Treatment Market?
The primary entities in the opioid-induced constipation treatment market are leveraging strategic alliances to pioneer innovative drugs. These strategic alliances aid companies by amalgamating resources and proficiency, bolstering research and development skills, broadening their market presence, and hastening product commercialization - in turn propelling expansion and novelty in the opioid-induced constipation treatment sector. Citing a case in point, Kyowa Kirin Co. Ltd, a biotechnology firm from Japan, in November 2022, collaborated with Grünenthal GmbH, a pharmaceutical establishment based in Germany, in order to consolidate solutions for patients. Through this cooperation, they plan to amplify the growth and worldwide availability of an array of transformative pain management drugs, which include treatment for opioid-induced constipation, acute cancer pain, and osteoporosis.
Who Are the Key Players In The Opioid-Induced Constipation Treatment Market?
Major companies operating in the opioid-induced constipation treatment market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Bayer AG
• Sanofi S.A.
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Daiichi Sankyo Chemical Pharma Co. Ltd.
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH.
• Shionogi & Co. Ltd.
• Ono Pharmaceutical Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals plc
• Mundipharma International Limited
• Lantheus Holdings Inc.
• Indivior plc
• Mallinckrodt Pharmaceuticals
• Collegium Pharmaceutical Inc.
• Ironwood Pharmaceuticals Inc.
• Cosmo Pharmaceuticals SA
• Nektar Therapeutics
• RedHill Biopharma Ltd.
• Theravance Biopharma Inc.
• Cumberland Pharmaceuticals Inc.
• Valinor Pharma LLC
What Are The Regional Insights Into The Opioid-Induced Constipation Treatment Market?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
